Canada approves plant-based Covid-19 vaccine
Medicago and GSK collaborated on Covifenz, an adjuvanted plant-based vaccine
Medicago and GSK collaborated on Covifenz, an adjuvanted plant-based vaccine
The facility will manufacture its Herceptin biosimilar, Tuznue
The brand has added a range of exciting new products especially formulated for oily skin.
Adds five years of market exclusivity on approval
Fast, flexible space allows clinical trials to start when needed. A trial can become operational, pivot or scale without traditional capital building expenditures
Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
MultiTEP Platform-based vaccine targeting three B cell epitopes of pathological ?-Synuclein simultaneously shows protective efficacy in mouse model of synucleinopathies
Sucharita brings with her a rich and varied experience of two decades in Information Technology and Financial Services
Subscribe To Our Newsletter & Stay Updated